Correction to: Assessment of the Cost-Effectiveness of HER2-Targeted Treatment Pathways in the Neoadjuvant Treatment of High-Risk HER2-Positive Early-Stage Breast Cancer.

Sussell, Jesse A; Roth, Joshua A; Meyer, Craig S; Fung, Anita; Hansen, Svenn A

Sussell, Jesse A; Roth, Joshua A; Meyer, Craig S; Fung, Anita; Hansen, Svenn A.

Afiliação

Sussell JA; Evidence for Access, US Medical Affairs, Genentech, South San Francisco, CA, USA. sussellj@gene.com.
Roth JA; Evidence for Access, US Medical Affairs, Genentech, South San Francisco, CA, USA.
Meyer CS; Evidence for Access, US Medical Affairs, Genentech, South San Francisco, CA, USA.
Fung A; US Medical Affairs, Genentech, South San Francisco, CA, USA.
Hansen SA; F. Hoffmann-La Roche, Basel, Switzerland.

Adv Ther ; 39(7): 3423, 2022 Jul.

Article em En | MEDLINE | ID: mdl-35524841

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Health_economic_evaluation / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google